Maple 
CJC-1295 Ipamorelin blend Canada from Maple Research Labs combines two complementary growth hormone secretagogue peptides in a single 10mg research vial with verified 99.55% HPLC-UV purity.
The CJC-1295 Ipamorelin blend combines two of the most extensively studied growth hormone secretagogue peptides into a single 10mg research vial. This blend contains 5mg of CJC-1295 (No DAC), also known as Mod GRF 1-29, and 5mg of Ipamorelin, a selective growth hormone releasing peptide. Researchers in Canada studying the synergistic mechanisms of GHRH analogs and GHRPs can access both compounds in a pre-blended, research-ready format from Maple Research Labs.
CJC-1295 Ipamorelin Blend Canada Research Overview
Researchers across Canada choose Maple Research Labs for verified purity. Orders placed by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.
Research Background on CJC-1295 Ipamorelin Blend
CJC-1295 (No DAC) is a modified growth hormone releasing hormone analog consisting of 29 amino acids with substitutions at positions 2, 8, 15, and 27 to improve metabolic stability and receptor binding affinity. In preclinical research, CJC-1295 has demonstrated the ability to stimulate growth hormone secretion through the GHRH receptor pathway while maintaining the pulsatile release pattern that characterizes physiological growth hormone regulation. Research by Ionescu and Bhatt (2006) examined the pharmacokinetic properties of modified GRF analogs, establishing the foundation for ongoing research into this peptide class.
Ipamorelin is a pentapeptide growth hormone secretagogue that acts through the ghrelin receptor (GHS-R1a) to stimulate growth hormone release. Unlike other GHRPs, Ipamorelin has been shown in animal models to exhibit high selectivity for growth hormone release without significantly affecting cortisol, prolactin, or ACTH levels. Research by Raun et al. (1998) characterized Ipamorelin as a potent and selective growth hormone secretagogue in preclinical models, distinguishing it from earlier generation GHRPs with broader endocrine effects.
Synergistic Research Applications of This Blend
The combination of CJC-1295 and Ipamorelin in a single research blend allows investigators to study the synergistic interaction between GHRH-pathway and ghrelin-pathway stimulation of growth hormone release. These two mechanisms operate through distinct receptor systems and intracellular signaling cascades, and preclinical evidence suggests that concurrent activation may produce a greater growth hormone response than either compound alone. This CJC-1295 Ipamorelin blend supplies both compounds in a single lyophilised vial.
Product Specifications
- CAS Number: Blend (CJC-1295: 863288-34-0 / Ipamorelin: 170851-70-4)
- Molecular Formula: Blend
- Molecular Weight: CJC-1295: 3367.97 g/mol / Ipamorelin: 711.85 g/mol
- Tested 10mg blend sample: 99.55% HPLC-UV relative-area purity (report DBAV-CJCI-10-051226-02). The report gives one purity figure, not separate purity results for each component.
- Form: Lyophilized powder
- Quantity: 10mg per vial (5mg CJC-1295 No DAC + 5mg Ipamorelin)
Reconstitution and Storage Guidelines
Reconstitute this CJC-1295 Ipamorelin blend with bacteriostatic water by injecting the solvent slowly along the vial wall. Do not shake the vial. Gently swirl until the lyophilized powder is fully dissolved. Store the sealed vial at minus 20 degrees Celsius for long-term preservation or at 2 to 8 degrees Celsius for short-term storage of up to 90 days. Protect from light and repeated freeze-thaw cycles.
Quality Assurance at Maple Research Labs
Published reports describe the analyses performed on tested samples. An aggregate HPLC area percentage does not by itself establish purity for each blend component. Third-party certificates of analysis for tested lots are published on our COA page. Check the report’s compound, tested size, date, method and results. Published reports describe tested samples, not proof of each shipping unit or the lot currently shipping. HPLC-UV area-percent is a method-specific relative-area result, not independent molecular identity, absolute content, sterility, endotoxin status or safety. Separate identity or content results apply only where the individual report explicitly includes them. This commitment to analytical transparency is the foundation of our reputation among Canadian peptide researchers and distinguishes Maple Research Labs from suppliers who do not provide independent verification of their products.
This is a dual-peptide formulation; consult available sample-specific analytical documentation. Published certificates describe tested samples and do not establish that every vial was independently tested. Orders placed by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.
Related Research Peptides from Maple Research
Researchers studying growth hormone secretagogue pathways may also be interested in the individual components available separately: CJC-1295 (No DAC) and Ipamorelin 5MG. For researchers exploring the DAC-modified variant, we also offer CJC-1295 DAC. Consult available tested-sample reports for analytical documentation. Orders placed by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.
Certificate of Analysis
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Join the research list
New arrivals, current pricing, and research breakdowns. New arrivals, current pricing, and research breakdowns. Unsubscribe anytime.
